CLYYF (Celyad Oncology) Total Current Assets: $4.10 Mil (As of Dec. 2025)

What is Celyad Oncology Total Current Assets?

Celyad Oncology CLYYF 13 Total Current Assets is $4.10 Mil as of Dec. 2025. GuruFocus rates CLYYF with a GF Score™ of 13/100 and a GF Value™ of $0.44 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Celyad Oncology's total current assets for the quarter that ended in Dec. 2025 was $4.10 Mil.

Celyad Oncology (OTCPK:CLYYF) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Celyad Oncology's Liquidation Value for the quarter that ended in Dec. 2025 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2	-	2.18	+	0.75 * 0.013	+	0.5 * 0
=	-0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celyad Oncology Total Current Assets Related Terms

Celyad Oncology Total Current Assets Historical Data

* Premium members only.

The historical data trend for Celyad Oncology's Total Current Assets can be seen below:

Celyad Oncology Total Current Assets Chart

Celyad Oncology Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Current Assets

Get a 7-Day Free Trial

38.75

15.70

12.13

6.82

4.10

Celyad Oncology Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
Total Current Assets	Get a 7-Day Free Trial															12.13	9.33	6.82	2.83	4.10

13GF Score

Celyad Oncology SA CLYYF

Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Celyad Oncology Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Celyad Oncology's Total Current Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	2	+	0.817	+	0	+	1.278
	=	4.10

Celyad Oncology's Total Current Assets for the quarter that ended in Dec. 2025 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	2	+	0.817	+	0	+	1.278
	=	4.10

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →

What does a Total Current Assets of $4.10 Mil mean?

Celyad Oncology (CLYYF) has a Total Current Assets of $4.10 Mil as of Dec. 2025. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Celyad Oncology and its competitors.

Is Celyad Oncology's Total Current Assets too high?

Celyad Oncology's current Total Current Assets is $4.10 Mil. Overall, Celyad Oncology has a GF Score™ of 13/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Celyad Oncology's Total Current Assets compare to VRTX and REGN?

Celyad Oncology's Total Current Assets of $4.10 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Current Assets for a Biotechnology company?

A good Total Current Assets depends on the Biotechnology industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Current Assets mean?

A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Celyad Oncology and its competitors. Celyad Oncology's current Total Current Assets is $4.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Celyad Oncology stock overvalued right now?

Based on GuruFocus' analysis, Celyad Oncology (CLYYF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.44, compared to a current price of $0.25 — trading 43.2% below its estimated fair value. The current Total Current Assets is $4.10 Mil. Celyad Oncology's overall GF Score™ is 13/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Current Assets calculated?

Total Current Assets is calculated from a company's financial statements. For Celyad Oncology (CLYYF), the current Total Current Assets is $4.10 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celyad Oncology (CLYYF) Overvalued in 2026?

Based on GuruFocus' analysis, Celyad Oncology stock appears to be undervalued. The current stock price of $0.25 is trading 43.2% below its estimated GF Value™ of $0.44. GuruFocus considers Celyad Oncology to be Significantly Overvalued.

Key valuation signals for CLYYF:

Total Current Assets: $4.10 Mil
GF Value™: $0.44 vs. price of $0.25 (43.2% below fair value)
GF Score™: 13/100 with 6 warning signs

No single metric tells the full story. See the CLYYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celyad Oncology Business Description

Industry Healthcare Biotechnology

Comparable Companies XBRU:ALEMS XBRU:OXUR VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270 RPRX BNTX INSM ROIV INCY MRNA HKSE:01801 HKSE:02269

Other Exchanges 0QFK:UK 1C0:Germany CYAD:Belgium

Address Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435

Website https://www.celyad.com

Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.

13GF Score

Get the complete analysis for CLYYF

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25

Price

$0.44

GF Value

View CLYYF Analysis

See Total Current Assets data for all stocks →